“Next generation transcriptomics-based precision oncology”
Precision oncology has made significant advances, mainly by targeting actionable mutations and fusion events involving cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun to explore the utility of tumor transcriptome in guiding patients’ treatment. I will first describe SELECT and ENLIGHT, which aim to predict patient response from the bulk tumor transcriptome. Second, PERCEPTION, which aims to do that from tumor single cell expression, considering tumor heterogeneity. Thirdly, I will present ENLIGHT-DeepPT, a precision oncology expression-based approach that starts from tumor histopathological images. Finally, I will discuss our ongoing work on LIQUID-BASED TRANSCRIPTOMICS (LBT), aiming to harness both bulk and single-cell white blood cells (WBC) expression, to infer the tumor immune microenvironment and predict patients’ response from the blood.